| Old Articles: <Older 5801-5810 Newer> |
|---|
 |
The Motley Fool
July 31, 2009
Brian Orelli |
Make Money Off Baby Boomers They're getting older whether they like it or not and need blood pressure, osteoporosis, and arthritis drugs and therapies.   |
The Motley Fool
July 30, 2009
Robert Steyer |
Covance Advances Covance latest results produce more optimism than did some of its contract research peers. |
The Motley Fool
July 30, 2009
Brian Orelli |
A Little Help From the Enemy Unfortunately, it won't last. AstraZeneca went over a small patent cliff, but its competitors were nice enough to throw it some climbing gear. |
The Motley Fool
July 30, 2009
Brian Orelli |
Merck, Sanofi, and Schering's Love Triangle Perhaps the most complicated deal of the year. |
BusinessWeek
July 29, 2009
Arlene Weintraub |
Teva Fights for Biotech Generics Teva's Debra Barrett is lobbying hard to shorten the protection period for biotech drugs and get generic versions to market more quickly |
The Motley Fool
July 29, 2009
Brian Orelli |
Ignore These Companies at Your Peril You may not want to invest in them, but don't ignore them. |
The Motley Fool
July 29, 2009
Brian Orelli |
The Swine Flu Can't Save Sanofi No shocker there. |
The Motley Fool
July 28, 2009
Brian Orelli |
All Growth, All the Time This generic-drug maker is no value play. |
The Motley Fool
July 28, 2009
Brian Orelli |
Amgen Secures Its Future Earnings and a marketing partnership -- oh my. |
The Motley Fool
July 28, 2009
Brian Orelli |
I Can't Believe My Company Got Acquired Would you like some cheese with that whining? Investors buy into a biotech company hoping for a 10-bagger after a drug is approved. Instead, they end up getting capped at a double when the biotech gets acquired. |
| <Older 5801-5810 Newer> Return to current articles. |
